ShapeShapeauthorShapechevroncrossShapeShapeShapeGrouphamburgerhomeGroupmagnifyShapeShapeShaperssShape

New Pfizer Animal Health is Unveiled

by 5m Editor
20 October 2009, at 10:30am

US - Following the acquisition of Wyeth, the addition of Fort Dodge Animal Health products diversifies and enhances Pfizer's already robust US portfolio.

A new Pfizer Animal Health was unveiled last week as Pfizer's acquisition of Wyeth, including its subsidiary Fort Dodge Animal Health, was completed. Pfizer Animal Health is now the world's leader in the discovery, development, manufacture and sales of veterinary vaccines and medicines for livestock and companion animals.

The acquisition of many of Fort Dodge's US products allows Pfizer Animal Health to greatly diversify its US portfolio, as well as broaden its offering in all animal health segments. Pfizer Animal Health now offers an enhanced portfolio in beef, dairy and companion animals, as well as a redefined product line for swine, equine and poultry.

"We're extremely proud to offer our customers even more best-in-class and innovative products," said Clint Lewis, president of US Operations for Pfizer Animal Health. "The products, services and expertise we are gaining strengthen what is already a robust US portfolio and will enhance our leading position in the animal health marketplace."

There follows a summary of Pfizer Animal Health's new US product portfolio for livestock:

  • As the leader for beef and dairy animal health solutions, Pfizer will further enhance its position with the addition of Factrel (gonadorelin hydrochloride) and the proven and well-recognised pioneer line of Synovex implants. These products complement the current US cattle portfolio that includes Draxxin (tulathromycin), Dectomax, Excede (ceftiofur crystalline free acid), Excenel (ceftiofur hydrochloride), Bovi-Shield Gold, Lutalyse (dinoprost tromethamine), Orbeseal and Spectramast (ceftiofur hydrochloride). Pfizer Animal Genetics also continues to explore opportunities to apply genomics technology to livestock health and management solutions.

  • For the swine market, Pfizer Animal Health will offer a comprehensive range of solutions and services to strengthen its offering with the full line of Suvaxyn brands, including Suvaxyn PCV-2 vaccine for circovirus. This addition rounds out an already broad product line that includes Respisure, Flusure, Draxxin and Excede.

  • Already the world leader of in-ovo technology, Pfizer Poultry Health will strengthen its position in the poultry industry with the addition of a broad range of poultry vaccines including Poulvac and Maternavac IBD-Reo, a leading broiler breeder vaccine.

Pfizer Animal Health has also announced that all current US pricing, product distribution, programmes and policies for Pfizer Animal Health products, including the acquired Fort Dodge products, will remain in place through 2009.

"Pfizer Animal Health is passionate about working hand-in-hand with our customers and partners to transform the care, health and well-being of animals," Mr Lewis said. "We continue to envision a future where animal health care providers, veterinarians and livestock producers look to Pfizer first to help them to run their practice or operation productively and profitably. With our newly expanded portfolio, value-added services and high-calibre talent, Pfizer is more focused than ever on providing relevant solutions to their animal care needs."